Stuttgart
09.09.26 | 13:03
0,700 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | Egetis Therapeutics AB: Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan | 166 | GlobeNewswire (Europe) | Stockholm, Sweden, August 31, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that its partner Fujimoto Pharmaceutical Corporation, which has... ► Artikel lesen | |
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Earnings call transcript: Egetis Therapeutics steigert Umsatz und visiert US-Markteinführung für Emcitate an | 1 | Investing.com Deutsch | ||
| 21.08. | Egetis Therapeutics AB Q2 Sales Increase | 1 | RTTNews | ||
| 21.08. | Egetis Therapeutics AB: Egetis' Interim report Q2 2026 | 324 | GlobeNewswire (Europe) | FDA's review of Emcitate® NDA progressing according to plan towards September 28, 2026, PDUFA action dateEgetis granted patent for MCT8 Deficiency Composition in the U.S.Emcitate sales in Europe during... ► Artikel lesen | |
| 10.06. | Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency | 448 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 10, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(Nasdaq Stockholm:EGTX), an innovative pharmaceutical company focused on late-stage... ► Artikel lesen | |
| 10.06. | Egetis Therapeutics AB: Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency | 229 | GlobeNewswire (Europe) | Stockholm, Sweden, June 10, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization... ► Artikel lesen | |
| 19.05. | Egetis Therapeutics: Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026 | 525 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference... ► Artikel lesen | |
| 07.05. | Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 | 489 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm:EGTX) today announced that the Company is planning to participate in several... ► Artikel lesen | |
| 05.05. | Egetis Therapeutics: Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S. | 460 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO)... ► Artikel lesen | |
| 30.04. | Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026 | 286 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced its participation... ► Artikel lesen | |
| 29.04. | Egetis Therapeutics AB: Interim report Q1 2026 | 1.007 | GlobeNewswire (Europe) | Egetis Announced FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency · Egetis completed the U.S. New Drug Application (NDA) for Emcitate® in January· ... ► Artikel lesen | |
| 21.04. | Egetis Therapeutics AB: Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million) | 214 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 14.04. | Egetis Therapeutics AB: Bulletin from Egetis Therapeutics' Annual General Meeting 2026 | 360 | GlobeNewswire (Europe) | Stockholm, Sweden, April 14, 2026. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on April 14, 2026, at which the submitted proposals were... ► Artikel lesen | |
| 09.04. | Egetis Therapeutics: Egetis Appoints Tiago Nunes as Chief Medical Officer | 766 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer... ► Artikel lesen | |
| 27.03. | Egetis Therapeutics: Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate for MCT8 Deficiency | 763 | ACCESS Newswire | NDA submission for Emcitate successfully validated by the FDAPriority Review granted and PDUFA target action date set to September 28, 2026Emcitate (tiratricol) is eligible to receive a Priority Review... ► Artikel lesen | |
| 09.03. | Egetis Therapeutics: Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. | 466 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office... ► Artikel lesen | |
| 02.03. | Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers | 418 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / March 2, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced the launch of two updated educational websites... ► Artikel lesen | |
| 26.02. | Egetis Therapeutics AB: Year-End Report January-December 2025 | 416 | GlobeNewswire (Europe) | Egetis submitted the U.S. NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency· Emcitate® revenue during 2025 amounted to MSEK 62.3, a 40 % increase in constant exchange rates from... ► Artikel lesen | |
| 16.02. | Egetis Therapeutics AB: Egetis provides update on progress with the development of Emcitate (tiratricol) for MCT8 deficiency in Japan | 365 | GlobeNewswire (Europe) | Stockholm, Sweden, February 16, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that its Japanese partner Fujimoto Pharmaceuticals, who has... ► Artikel lesen | |
| 04.02. | Egetis Therapeutics AB: FDA's rare pediatric disease priority review program extended until 2029 | 479 | GlobeNewswire (Europe) | Stockholm, Sweden, February 4, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today noted that the U.S. Food and Drug Administration's (FDA's) Rare Pediatric... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 73,78 | -1,30 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in seinem am Mittwoch vorliegenden... ► Artikel lesen | |
| GSK | 20,990 | +0,33 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 2000 Pence auf "Hold" belassen. Dies schrieb Emmanuel Papadakis in seinem am Mittwoch vorliegenden... ► Artikel lesen | |
| ASTRAZENECA | 136,70 | -0,73 % | DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca mit einem Kursziel von 11500 Pence auf "Sell" belassen. Dies schrieb Emmanuel Papadakis in seinem am Mittwoch... ► Artikel lesen | |
| TILRAY BRANDS | 3,780 | +2,30 % | Tilray Brands, Inc.: BrewDog steigt mit einer fünfjährigen Partnerschaft mit den Leicester Tigers in den Rugby-Sport ein und bringt Punk-Energie in die Welford Road | ELLON, Schottland und LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BrewDog, ein führender Anbieter von Craft-Bier im Vereinigten Königreich und eine der weltweit bekanntesten Craft-Bier-Marken, hat... ► Artikel lesen | |
| DERMAPHARM | 38,600 | -0,90 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,678 | -2,48 % | XFRA 0K91: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILQUANTUM BIOPHARMA... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 11,010 | -2,70 % | Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report | ||
| FILANA THERAPEUTICS | 0,693 | -0,29 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 12,050 | +0,42 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,350 | +3,05 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| SOLIGENIX | 0,375 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,180 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants | NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE:... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,249 | +0,40 % | Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results | - First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic... ► Artikel lesen | |
| BAYER | 48,980 | -0,87 % | Bayer Aktie: Es brodelt unter dem Deckel | Es bleibt spannend: Die Bayer Aktie kommt aus ihrer engen Tradingspanne bisher nicht heraus. Der DAX-Titel pendelt weiter seitwärts, eingeklemmt zwischen dem verteidigten Boden im 45er-Bereich und dem... ► Artikel lesen | |
| MERCK KGAA | 131,15 | -2,56 % | JEFFERIES stuft MERCK KGAA auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA mit einem Kursziel von 144 Euro auf "Hold" belassen. Nach jüngst dem Life-Science-Bereich widmete sich James... ► Artikel lesen |
Das Unternehmen EGETIS THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.